Genmab A/S - Notice to Convene Annual Gener...(ators of inflammation. He was instrument...)

Date:4/7/2008

ators of inflammation. He was instrumental in the development of Enbrel, a soluble receptor for TNF marketed by Amgen and Wyeth Ayerst for the treatment of rheumatoid arthritis. He received a Ph.D. in genetics from the University of Wisconsin in 1976 and completed a postdoctoral fellowship in Immunology at the Swiss Institute for Experimental Cancer Research in Lausanne, Switzerland.

About Karsten Havkrog Pedersen

Mr. Pedersen has been a member of our board since March 2002. He has more than 25 years experience as an attorney within Danish corporate law and corporate governance. Mr. Pedersen has been a partner in the law firm Hjejle, Gersted & Mogensen since 1981. He was admitted as barrister to the Supreme Court of Justice in 1983. Mr. Pedersen was a member of the Danish Appeal Board (2000-2003) and was a member of the Danish Bar and Law Society, Committee of Legal Affairs (2001-2007). From 1991-2004, he was a member of the Editorial Committee of the Danish legal magazine Lov & Ret. Mr. Pedersen is a member of the board for BIG Fonden and its subsidiaries and other Danish legal entities.

5. Election of auditor.

The Board of Directors proposes re-election of PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab A/S as the Company's elected auditor.

6. Proposals from the Board of Directors and/or the shareholders:

(a) All warrants granted pursuant to the current Article 5 have been exercised or have lapsed as non exercised on 26 September 2007. Consequently, it is proposed that both the current Article 5 of the Articles of Association and the related Schedule A are removed from the Articles.

(b) The contents of Article 6 of the Articles of Association have been removed on August 30, 2005 and it is proposed that the reference to this removal is deleted.

(c) As a reflection of the removal of Articles 5 and 6, cf. (a) and (b) above, it is proposed that the current Article 6A will be renumbered Article 5. T
'/>"/>

SOURCE Genmab A/S Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Genmabs 2007 Annual Report
2. Genmab Announces Year End 2007 Financial Results
3. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
4. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
5. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
6. Medarex Announces Completion of Sale of Shares in Genmab A/S
7. Genmabs Financial Calendar for 2008
8. Genmab Reaches Milestones in Ofatumumab Collaboration
9. Genmab Announces HuMax-CD32b Pre-Clinical Program
10. Roche Files IND for Second Genmab Antibody
11. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma